Shares of Eli Lilly (NYSE: LLY ) lagged the broader market in 2013 by a wide margin. While some investors may see this as an opportunity to jump into a sector filled with sky-high valuations, it's important to first weigh both the pros and cons of this particular stock. In the following video, analyst Max Macaluso focuses on one headwind, namely the affect of the "patent cliff" on Lilly's top and bottom lines, and one tailwind, the drugs Lilly is developing, that will have huge impacts on the stock this year.
The Motley Fool's Top Stock for 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.